

Caicun Zhou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5202984/publications.pdf>

Version: 2024-02-01

47
papers

11,377
citations

279487

23
h-index

214527

47
g-index

47
all docs

47
docs citations

47
times ranked

10952
citing authors

#	ARTICLE	IF	CITATIONS
1	Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2011, 12, 735-742.	5.1	3,758
2	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <i>Lancet</i> , The, 2019, 393, 1819-1830.	6.3	2,347
3	Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 213-222.	5.1	1,740
4	Durvalumab plus platinum-epitoposide versus platinum-epitoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. <i>Lancet</i> , The, 2019, 394, 1929-1939.	6.3	1,274
5	BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2197-2204.	0.8	323
6	Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2015, 33, 1958-1965.	0.8	280
7	Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1085-1097.	0.5	202
8	Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1383-1392.	0.5	140
9	Lung cancer in never smokers—the East Asian experience. <i>Translational Lung Cancer Research</i> , 2018, 7, 450-463.	1.3	104
10	The cutting-edge progress of immune-checkpoint blockade in lung cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 279-293.	4.8	102
11	Renal-Clearable Hollow Bismuth Subcarbonate Nanotubes for Tumor Targeted Computed Tomography Imaging and Chemoradiotherapy. <i>Nano Letters</i> , 2018, 18, 1196-1204.	4.5	101
12	High-resolution computed tomography manifestations of COVID-19 infections in patients of different ages. <i>European Journal of Radiology</i> , 2020, 126, 108972.	1.2	92
13	The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer. <i>Cancer</i> , 2014, 120, 2299-2307.	2.0	84
14	Genomic landscape and its correlations with tumor mutational burden, PD-L1 expression, and immune cells infiltration in Chinese lung squamous cell carcinoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 75.	6.9	84
15	T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. <i>Lung Cancer</i> , 2014, 84, 295-300.	0.9	81
16	Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients. <i>Translational Oncology</i> , 2014, 7, 341-348.	1.7	68
17	Featured Gut Microbiomes Associated With the Progression of Chronic Hepatitis B Disease. <i>Frontiers in Microbiology</i> , 2020, 11, 383.	1.5	57
18	Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. <i>Cancer</i> , 2012, 118, 5588-5594.	2.0	52

#	ARTICLE	IF	CITATIONS
19	WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. <i>Cell Communication and Signaling</i> , 2019, 17, 109.	2.7	45
20	Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes. <i>Annals of Translational Medicine</i> , 2020, 8, 141-141.	0.7	44
21	Imaging features of TSCT predict the classification of pulmonary preinvasive lesion, minimally and invasive adenocarcinoma presented as ground glass nodules. <i>Lung Cancer</i> , 2017, 108, 192-197.	0.9	37
22	High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients. <i>Surgical Oncology</i> , 2015, 24, 220-225.	0.8	34
23	Dynamic volume perfusion CT in patients with lung cancer: Baseline perfusion characteristics of different histological subtypes. <i>European Journal of Radiology</i> , 2013, 82, e894-e900.	1.2	29
24	Randomized study of individualized pharmacokinetically guided dosing of paclitaxel compared with body surface area dosing in Chinese patients with advanced non-small cell lung cancer. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2292-2301.	1.1	26
25	Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases. <i>Scientific Reports</i> , 2017, 7, 42979.	1.6	24
26	Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations. <i>Journal of Thoracic Disease</i> , 2017, 9, 2923-2934.	0.6	23
27	Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. <i>Thoracic Cancer</i> , 2020, 11, 2812-2819.	0.8	23
28	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations – Still a daily challenge. <i>European Journal of Cancer</i> , 2017, 83, 266-278.	1.3	22
29	Dynamic Volume Perfusion Computed Tomography Parameters versus RECIST for the Prediction of Outcome in Lung Cancer Patients Treated with Conventional Chemotherapy. <i>Journal of Thoracic Oncology</i> , 2015, 10, 164-171.	0.5	19
30	Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?. <i>Lung Cancer</i> , 2018, 116, 30-37.	0.9	19
31	Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy. <i>Frontiers in Immunology</i> , 2022, 13, 840313.	2.2	19
32	Indirubin Derivative 7-Bromoindirubin-3-Oxime (7Bio) Attenuates A β ² Oligomer-Induced Cognitive Impairments in Mice. <i>Frontiers in Molecular Neuroscience</i> , 2017, 10, 393.	1.4	16
33	The Role of Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 671874.	1.3	14
34	The Association Between Imaging Features of TSCT and the Expression of PD-L1 in Patients With Surgical Resection of Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2019, 20, e195-e207.	1.1	11
35	9-Methylfascaplysin exerts anti-ischemic stroke neuroprotective effects via the inhibition of neuroinflammation and oxidative stress in rats. <i>International Immunopharmacology</i> , 2021, 97, 107656.	1.7	10
36	Design and synthesis of novel tacrine-dipicolylamine dimers that are multiple-target-directed ligands with potential to treat Alzheimer's disease. <i>Bioorganic Chemistry</i> , 2021, 116, 105387.	2.0	10

#	ARTICLE	IF	CITATIONS
37	Clinicopathologic features and lymph node metastatic characteristics in patients with adenocarcinoma manifesting as part-solid nodule exceeding 3 cm in diameter. <i>Lung Cancer</i> , 2019, 136, 37-44.	0.9	9
38	Identification of tumorigenicity-associated genes in osteosarcoma cell lines based on bioinformatic analysis and experimental validation. <i>Journal of Cancer</i> , 2020, 11, 3623-3633.	1.2	9
39	Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. <i>Lung Cancer</i> , 2022, 167, 25-33.	0.9	9
40	The Association between COX-2 Polymorphisms and Hematologic Toxicity in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Platinum-Based Chemotherapy. <i>PLoS ONE</i> , 2013, 8, e61585.	1.1	8
41	Carfilzomib inhibits the growth of lung adenocarcinoma via upregulation of Gadd45a expression. <i>Journal of Zhejiang University: Science B</i> , 2020, 21, 64-76.	1.3	7
42	Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs. <i>BMC Cancer</i> , 2018, 18, 1033.	1.1	5
43	Preparation of Mn ²⁺ @PolyDOPA-b-polysarcosine micelle as MRI contrast agent with high longitudinal relaxivity. <i>Journal of Macromolecular Science - Pure and Applied Chemistry</i> , 2021, 58, 175-181.	1.2	5
44	Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint. <i>Journal of Thoracic Oncology</i> , 2020, 15, 485-488.	0.5	4
45	Chemotherapy Should Be Combined With Checkpoint Inhibitors in the Treatment of Patients With Stage IV EGFR-Mutant NSCLC Whose Disease Has Progressed on All Available Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1622-1626.	0.5	4
46	A clinicopathological study of lung adenocarcinomas with pure ground-glass opacity > 3 cm on high-resolution computed tomography. <i>European Radiology</i> , 2022, 32, 174-183.	2.3	2
47	Combined treatment of cholangiocarcinoma with interventional radiofrequency hyperthermia and heat shock protein promoter-mediated HSV-TK gene therapy. <i>American Journal of Cancer Research</i> , 2018, 8, 1595-1603.	1.4	1